Tumor Infiltrating Lymphocyte
Phase 1Cell therapy
Tumor Infiltrating Lymphocyte is one of 87 biologic programs targeting Melanoma. It is currently in Phase 1.
3
Indications
3
Total Trials
2
Active Trials
86
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
MS Contin
Merck & Co.Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
LDE225
NovartisPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Meglitinides
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- SShanghai Juncell Therapeutics